Design, synthesis and biological evaluation of new tricyclic spiroisoxazoline derivatives as selective COX-2 inhibitors and study of their COX-2 binding modes via docking studies

被引:15
作者
Abolhasani, Hoda [1 ,2 ]
Dastmalchi, Siavoush [2 ]
Hamzeh-Mivehroud, Maryam [2 ]
Daraei, Bahram [3 ]
Zarghi, Afshin [4 ]
机构
[1] Qom Univ Med Sci, Dept Pharmacol, Fac Med, Qom, Iran
[2] Tabriz Univ Med Sci, Sch Pharm, Dept Med Chem, Tabriz, Iran
[3] Tarbiat Modares Univ, Fac Med Sci, Dept Toxicol, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Med Chem, Tehran, Iran
关键词
Spiroisoxazoline; 1,3-Dipolar cycloaddition; Molecular modeling; Docking; GENETIC ALGORITHM; CANCER; ROFECOXIB; ADENOMAS; INCREASE; CELLS;
D O I
10.1007/s00044-016-1534-x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A new series of 3'-(4-substitutedphenyl)-4'-(4-(methylsulfonyl)phenyl) spiroisoxazoline derivatives containing naphthalenone and chromanonespiro-bridge were synthesized for evaluation as selective cyclooxygenase-2 (COX-2) inhibitors. A synthetic reaction based on the 1,3-dipolar cycloaddition mechanism was used for the regiospecific formation of various spiroisoxazolines. One of the analogs, i.e., compound 7h, as the representative of the series was recrystallized and characterized structurally by single-crystal X-ray diffraction method. Moreover, the 3D structures of the synthesized compounds were docked into the COX-2 binding site to determine their most probable binding modes once the drug-receptor complexes are formed.
引用
收藏
页码:858 / 869
页数:12
相关论文
共 34 条
[1]   Drug design of new antitubercular agents: 1,3-dipolar cycloaddition reaction of para-substituted-benzadoximes and 3-para-methoxy-benzyliden-isochroman-4-ones [J].
Al Houari, Ghali ;
Kerbal, Abdelali ;
Bennani, Brahim ;
Baba, Mohamed F. ;
Daoudi, Maria ;
Ben Hadda, Taibi .
ARKIVOC, 2008, :42-50
[2]   CONFORMATIONAL-ANALYSIS .130. MM2 - HYDROCARBON FORCE-FIELD UTILIZING V1 AND V2 TORSIONAL TERMS [J].
ALLINGER, NL .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1977, 99 (25) :8127-8134
[3]  
[Anonymous], 2013, CSID 13611429 HWCCC
[4]  
BENNANI B, 2004, Patent No. 2771
[5]   Selective cyclooxygenase-2 inhibitors [J].
Black, WC .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 39, 2004, 39 :125-138
[6]   Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer [J].
Chell, Simon ;
Kadi, Abderrahmane ;
Williams, Ann Caroline ;
Paraskeva, Christos .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2006, 1766 (01) :104-119
[7]   GROUND-STATES OF MOLECULES .39. MNDO RESULTS FOR MOLECULES CONTAINING HYDROGEN, CARBON, NITROGEN, AND OXYGEN [J].
DEWAR, MJS ;
THIEL, W .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1977, 99 (15) :4907-4917
[8]   Adverse cardiovascular effects of the coxibs [J].
Dogné, JM ;
Supuran, CT ;
Pratico, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) :2251-2257
[9]   UP-REGULATION OF CYCLOOXYGENASE-2 GENE-EXPRESSION IN HUMAN COLORECTAL ADENOMAS AND ADENOCARCINOMAS [J].
EBERHART, CE ;
COFFEY, RJ ;
RADHIKA, A ;
GIARDIELLO, FM ;
FERRENBACH, S ;
DUBOIS, RN .
GASTROENTEROLOGY, 1994, 107 (04) :1183-1188
[10]   More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib [J].
Hinz, B ;
Dormann, H ;
Brune, K .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :282-291